ReviewFuture oncology (London, England)2018
The utility of
Review in Future oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 81 citations in OpenAlex.
- Automated and manual synthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- The prognostic effect of dualBMC gastroenterology · 2026Article
- Severe Ectopic ACTH-Dependent Cushing Syndrome Due to a Neuroendocrine Tumor of Occult Primary Origin Presenting with Widespread Metastases and Early Vertebral Fractures: A Rare Case Report.International medical case reports journal · 2026Article
- [Oncology letters · 2025Article
- Diagnosis and treatment of renal neuroendocrine tumors: a case report and literature review.Frontiers in oncology · 2025Article
- Deep-learning-based Attenuation Correction forMolecular imaging and radionuclide therapy · 2024Article
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Comparison ofCurrent oncology (Toronto, Ont.) · 2024Article
- Two synchronous primary mesenteric neuroendocrine tumors in a patient: a case report.Frontiers in surgery · 2024Article
- Review
- Neuroendocrine hepatic metastatic disease: the surgeon's perspective.Abdominal radiology (New York) · 2022Article
- An unusual case of chronic diarrhea: a case report.Internal and emergency medicine · 2022Article
- Highly variable biodistribution ofHepatobiliary surgery and nutrition · 2022Article
- Two birds with one stone: can [68Ga]Ga-DOTANOC PET/CT image quality be improved through BMI-adjusted injected activity without increasing acquisition times?The British journal of radiology · 2022Article
- Value of [EJNMMI research · 2022Article
- Synthesis ofPharmaceutics · 2021Article
- Review
- Evaluation ofJournal of endocrinological investigation · 2021Article
- A novel read methodology to evaluate the optimal dose ofEJNMMI research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Neuroendocrine tumors (NETs) are rare neoplasms that emerge mainly from the GI tract, pancreas and respiratory tract. The incidence of NETs has increased more than sixfold in the last decades. NETs typically express somatostatin receptors on their cell surface, which can be targeted by 'cold' somatostatin analogs for therapy or by 'hot' radiolabeled somatostatin analogs for tumor localization and treatment. 68-Gallium-DOTA peptides (DOTATATE, DOTATOC, DOTANOC) positron emission tomography/computed tomography is a highly accurate imaging modality for NETs that has been found to be more sensitive for NET detection than other imaging modalities. In the current review, we will discuss the clinical utility of 68-Gallium-DOTATATE positron emission tomography/computed tomography for the diagnosis and management of patients with NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.